The Antiviral Activity of the Lectin Griffithsin against SARS-CoV-2 Is Enhanced by the Presence of Structural Proteins
Open Access
Abstract
Although COVID-19 transmission has been reduced by the advent of vaccinations and a variety of rapid monitoring techniques, the SARS-CoV-2 virus itself has shown a remarkable ability to mutate and persist. With this long track record of immune escape, researchers are still exploring prophylactic treatments to curtail future SARS-CoV-2 variants. Specifically, much focus has been placed on the antiviral lectin Griffithsin in preventing spike protein-mediated infection via the hACE2 receptor (direct infection). However, an oft-overlooked aspect of SARS-CoV-2 infection is viral capture by attachment receptors such as DC-SIGN, which is thought to facilitate the initial stages of COVID-19 infection in the lung tissue (called trans-infection). In addition, while immune escape is dictated by mutations in the spike protein, coronaviral virions also incorporate M, N, and E structural proteins within the particle. In this paper, we explored how several structural facets of both the SARS-CoV-2 virion and the antiviral lectin Griffithsin can affect and attenuate the infectivity of SARS-CoV-2 pseudovirus. We found that Griffithsin was a better inhibitor of hACE2-mediated direct infection when the coronaviral M protein is present compared to when it is absent (possibly providing an explanation regarding why Griffithsin shows better inhibition against authentic SARS-CoV-2 as opposed to pseudotyped viruses, which generally do not contain M) and that Griffithsin was not an effective inhibitor of DC-SIGN-mediated trans-infection. Furthermore, we found that DC-SIGN appeared to mediate trans-infection exclusively via binding to the SARS-CoV-2 spike protein, with no significant effect observed when other viral proteins (M, N, and/or E) were present. These results provide etiological data that may help to direct the development of novel antiviral treatments, either by leveraging Griffithsin binding to the M protein as a novel strategy to prevent SARS-CoV-2 infection or by narrowing efforts to inhibit trans-infection to focus on DC-SIGN binding to SARS-CoV-2 spike protein.Keywords
Funding Information
- Army Research Office (W911NF2010268, 2112675)
- NSF-CREST Center for Cellular and Biomolecular Machines (CCBM) (W911NF2010268, 2112675)
- COVID-19 funding program of the Health Science Research Institute at U.C. Merced (W911NF2010268, 2112675)
This publication has 104 references indexed in Scilit:
- lDDT: a local superposition-free score for comparing protein structures and models using distance difference testsBioinformatics, 2013
- Toward the estimation of the absolute quality of individual protein structure modelsBioinformatics, 2010
- Monomerization of Viral Entry Inhibitor Griffithsin Elucidates the Relationship between Multivalent Binding to Carbohydrates and anti-HIV ActivityStructure, 2010
- Anti-HIV Activity of Defective Cyanovirin-N Mutants Is Restored by DimerizationJournal of Biological Chemistry, 2010
- HIV-1 Transmission by Dendritic Cell-specific ICAM-3-grabbing Nonintegrin (DC-SIGN) Is Regulated by Determinants in the Carbohydrate Recognition Domain That Are Absent in Liver/Lymph Node-SIGN (L-SIGN)Journal of Biological Chemistry, 2010
- DC-SIGN Mediates Cell-Free Infection and Transmission of Human T-Cell Lymphotropic Virus Type 1 by Dendritic CellsJournal of Virology, 2009
- DC-SIGN Neck Domain Is a pH-sensor Controlling OligomerizationJournal of Biological Chemistry, 2009
- Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentProceedings of the National Academy of Sciences, 2009
- Multiple Modes of Binding Enhance the Affinity of DC-SIGN for High Mannose N-Linked Glycans Found on Viral GlycoproteinsJournal of Biological Chemistry, 2007
- DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic CellsJournal of Experimental Medicine, 2003